Liver glycogen as a marker of glucagon signaling at ADA 2020

The American Diabetes Association’s (ADA) 80th Scientific sessions is ongoing – this time as a 5-day virtual event.

Although significant advances have been made in diabetes medicine there remains substantial unmet medical need. For new candidate drugs, it is necessary to have sophisticated solutions and tools to investigate novel mechanisms of actions, efficacy and tissue distribution in clinical trials in order to guide development programme strategies.

Antaros Medical method implementation of 13C magnetic resonance spectroscopy (MRS) for assessing liver glycogen content without invasive biopsies is one such tool.

The method, relying on liver glycogen as a marker of glucagon signaling is ideal for studying complex interactions of dual or trigonal agonists, binding to several targets with different but also overlapping biological effects. While it is well-known that glucagon promotes glycogen conversion to glucose, in the absence of a suitable target engagement marker, this physiological response marker can act as a substitute.

Edvin Johansson, Senior Imaging Director at Antaros Medical comments: “This is a strong marker of glucagon receptor signaling and of pharmacodynamic effects”. Lars Johansson, CSO & founder, Antaros Medical, adds: “It meets the complexity in the new generation of Diabetes Type 2 therapies including both dual and trigonal agonists.”.

Link to presentation:  Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content

Pressify Share on Linkedin Share on Twitter